ArriVent BioPharma, Inc. financial data

Symbol
AVBP on Nasdaq
Location
Newtown Square, PA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 05 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1361% % -36%
Debt-to-equity 7.5% % 58%
Return On Equity -62% % -123%
Return On Assets -58% % -117%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44,201,622 shares 30%
Common Stock, Shares, Outstanding 42,452,251 shares 26%
Entity Public Float $762,664,165 USD 99%
Common Stock, Value, Issued $4,000 USD 33%
Weighted Average Number of Shares Outstanding, Basic 38,462,600 shares 22%
Weighted Average Number of Shares Outstanding, Diluted 38,462,600 shares 22%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $153,351,000 USD 94%
General and Administrative Expense $24,183,000 USD 58%
Operating Income (Loss) $177,534,000 USD -88%
Net Income (Loss) Attributable to Parent $166,308,000 USD -107%
Earnings Per Share, Basic -4.32 USD/shares -69%
Earnings Per Share, Diluted -4.32 USD/shares -69%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $45,540,000 USD -39%
Assets, Current $332,897,000 USD 47%
Operating Lease, Right-of-Use Asset $13,000 USD -92%
Other Assets, Noncurrent $190,000 USD 51%
Assets $333,169,000 USD 21%
Accounts Payable, Current $5,934,000 USD 57%
Employee-related Liabilities, Current $6,545,000 USD 57%
Accrued Liabilities, Current $19,997,000 USD 50%
Liabilities, Current $25,945,000 USD 50%
Operating Lease, Liability, Noncurrent $14,000 USD -92%
Liabilities $25,945,000 USD 50%
Accumulated Other Comprehensive Income (Loss), Net of Tax $14,000 USD
Retained Earnings (Accumulated Deficit) $404,641,000 USD -70%
Stockholders' Equity Attributable to Parent $307,224,000 USD 19%
Liabilities and Equity $333,169,000 USD 21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $68,008,000 USD -265%
Net Cash Provided by (Used in) Financing Activities $6,759,000 USD -96%
Net Cash Provided by (Used in) Investing Activities $36,821,000 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 42,452,251 shares 26%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $24,428,000 USD -115%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $45,540,000 USD -39%
Deferred Tax Assets, Valuation Allowance $109,270,000 USD 59%
Deferred Tax Assets, Gross $109,270,000 USD 59%
Operating Lease, Liability $14,000 USD -92%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $166,083,000 USD -106%
Lessee, Operating Lease, Liability, to be Paid $14,000 USD -93%
Operating Lease, Liability, Current $14,000 USD -91%
Lessee, Operating Lease, Liability, to be Paid, Year Two $14,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $14,000 USD -92%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $11,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $34,279,000 USD 105%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $711,847,000 USD 43%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $39,000 USD -44%
Share-based Payment Arrangement, Expense $12,520,000 USD 290%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%